CRL

Citrini's AI drug-discovery pick on October 20 was followed by unconfirmed target raises that lifted shares 9.33% on October 21.

Shares jumped 9.33% on 21 October amid disputed causes: investor day and analyst target raises, or a sector-wide rally with no company news.

Shares rose 15.07% in a week after Investor Day 2027-2030 targets, analyst target raises and a UBS upgrade to Buy with a $357 target.

Trade sites credit the 9.33% jump to the Pathway to Purpose plan and a UBS upgrade to Buy with a $357 target.

Citrini Research sector note on AI-driven drug discovery lifted CRL 5.14% to $315.45 on 1.35x average volume.

Strong sector rotation and analyst price target upgrades following raised FY2026 guidance drove the stock to a new 52-week high.

The stock rose after management reaffirmed FY2026 financial guidance at the upper end and unveiled its 2030 targets at Investor Day.

Shares surged after Charles River reported strong Q2 2026 earnings, returned to organic revenue growth, and raised full-year guidance.

CRL surged following strong Q2 2026 earnings, a return to positive organic revenue growth, raised full-year guidance, and analyst upgrades.

CRL stock surged following a strong Q2 2026 earnings beat and an across-the-board upward revision to full-year 2026 financial guidance.

The stock surged following a Morgan Stanley upgrade and the announcement of a strategic AI drug discovery partnership with Eli Lilly.

Morgan Stanley upgraded CRL to Overweight on signs that recovering biopharma funding is translating into increased R&D bookings.